

α 1-Antitrypsin monotherapy prolongs islet allograft survival in mice

Eli C. Lewis, Leland Shapiro, Owen J. Bowers, and Charles A. Dinarello*

Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, CO 80262

Contributed by Charles A. Dinarello, July 1, 2005

Islet transplantation for type 1 diabetic patients shows promising results with the use of nondiabetogenic immunosuppressive therapy. However, in addition to compromising the immune system of transplant recipients, long-term studies demonstrate that islet viability is impaired. Here, we demonstrate that, in the absence of immunosuppressive agents, monotherapy with clinical-grade human α 1-antitrypsin (hAAT), the major serum serine-protease inhibitor, prolongs islet graft survival and normoglycemia in transplanted allogeneic diabetic mice, lasting until the development of anti-hAAT antibodies. Compared to untreated or albumin-control-treated graft recipients, which rejected islets at day 10, AAT-treated mice displayed diminished cellular infiltrates and intact intragraft insulin production throughout treatment. Using peritoneal infiltration models, we demonstrate that AAT decreases allogeneic fibroblast-elicited natural-killer-cell influx by 89%, CD3-positive cell influx by 44%, and thioglycolate-elicited neutrophil emigration by 66%. AAT also extended islet viability in mice after streptozotocin-induced beta cell toxicity. *In vitro*, several islet responses to IL-1 β /IFN γ stimulation were examined. In the presence of AAT, islets displayed enhanced viability and inducible insulin secretion. Islets also released 36% less nitric oxide and 82% less macrophage inflammatory protein 1 α and expressed 63% fewer surface MHC class II molecules. TNF α release from IL-1 β /IFN γ -stimulated islet cells was reduced by 99%, accompanied by an 8-fold increase in the accumulation of membrane TNF α on CD45-positive islet cells. In light of the established safety record and the nondiabetogenic potential of AAT, these data suggest that AAT may be beneficial as adjunctive therapy in patients undergoing islet transplantation.

interleukin 1 | nitric oxide | TNF α

Islet damage and an increased incidence of diabetes are associated with the use of immunosuppressive drugs in organ transplantation and present a major obstacle for clinically applicable human islet transplantation (1). Therefore, the advent of nondiabetogenic steroid-free, immunosuppressive treatment protocols, such as rapamycin-based protocols, have greatly facilitated human islet transplantation (reviewed in ref. 2). However, although clinically effective, rapamycin-based protocols have been associated with an increased risk of hyperlipidemia and hypertension, limiting the applicability of islet transplantation to severe cases of diabetes type 1. Long-term follow-up studies reveal that the viability of engrafted islets is also compromised (3, 4).

α 1-Antitrypsin (AAT), the major serum serine-protease inhibitor, inhibits the enzymatic activity of neutrophil elastase, cathepsin G, proteinase 3, thrombin, trypsin, and chymotrypsin (reviewed in ref. 5). AAT may facilitate the survival of islet transplants in engrafted patients, because the inhibitor prevents inflammatory cytokine production, blocks immune cell infiltration and function, inhibits complement activation, and delays the development of diabetes in nonobese diabetic mice (5–12).

In the present study, we demonstrate that monotherapy with clinical grade human AAT (hAAT) prolongs graft survival in a mouse model of islet allograft rejection. To examine the mechanisms responsible for this protection, we measured the effects

of hAAT on peritoneal-cell infiltration and addressed the protective effects of hAAT on islets by studying IL-1 β /IFN γ -induced islet responses *in vitro* and streptozotocin (STZ)-induced islet toxicity *in vivo*.

Materials and Methods

Mice. C57BL/6 and DBA/2 females were purchased from The Jackson Laboratory. Experiments were approved by the University of Colorado Institutional Animal Care and Use Committee.

Islet Isolation, Transplantation, and *in Vitro* Responses. Five- to 6-week-old C57BL/6 mice were rendered hyperglycemic by STZ (225 mg/kg of body weight *i.p.*, Sigma) and were transplanted 5 days later. Islets were isolated from DBA/2 mice on the day of transplantation, as described in ref. 13. Briefly, mice were anesthetized, and pancreata were inflated with collagenase (1 mg/ml, type XI, Sigma), excised, and incubated for 40 min at 37°C. Digested pancreata were vortexed and filtered through a 500- μ m sieve and the pellet washed in HBSS containing 0.5% BSA (Sigma). The pellet was resuspended in RPMI medium 1640 supplemented with 10% FCS, 50 units/ml penicillin, and 50 μ g/ml streptomycin (Cellgro, Mediatech, Herndon, VA). Islets were collected on a 100- μ m cell strainer (BD, Falcon) and hand picked. For transplantation, 450 islets were washed and mounted on a standard 0.2-ml tip. Recipient mice were anesthetized, an abdominal-wall incision was made over the left kidney, and the islets were released into the renal subcapsular space through a puncture in the capsule, which was immediately sealed with 1-mm³ sterile absorbable gelatin sponge (Surgifoam, Ethicon, Somerville, NJ). Blood glucose levels were determined three times a week from tail blood by using a glucometer (Roche).

For *in vitro* studies, the islets were incubated at 37°C for 24 h before experiments. An insulin-induction assay was performed as described in ref. 14, by using a mouse-insulin ELISA kit (Merckodia, Metuchen, NJ). Immunohistochemistry was performed as described in ref. 15, by using anti-mouse-insulin antibody (Sigma) and staining reagents (VECTASTAIN ABC, Vector Laboratories). NO in islet supernatants was measured by using Griess reagent (Promega). Islet viability was assessed by using an XTT-based toxicology assay (Sigma).

Detection of Anti-hAAT Antibodies. Serum anti-human-AAT antibody level was determined as described in ref. 16, with the following modifications. Microtiter plates were coated with hAAT (2 μ g/ml, Aralast, Baxter, Westlake Village, CA) or human albumin (2 μ g/ml). Goat-anti-mouse IgG-peroxidase conjugate (R & D Systems) was used as secondary antibody to detect bound anti-hAAT antibodies.

Peritoneal Cellular Infiltrates. Thioglycolate (ThG) (1 ml, 3% wt/vol, Sigma) or allogeneic cells (1×10^7 freshly trypsinized

Abbreviations: hAAT, human α 1-antitrypsin; NK, natural killer; STZ, streptozotocin; TACE, TNF α -converting enzyme; ThG, thioglycolate.

*To whom correspondence should be addressed. E-mail: cdinarello@mac.com.

© 2005 by The National Academy of Sciences of the USA

NIH 3T3 cells per peritoneal inoculation) were injected i.p. into mice that were pretreated with 0.1 ml of saline or human albumin, AAT, or oxidized AAT. Lavage was performed at indicated time points. Mice were anesthetized by isoflurane inhalation and injected i.p. with PBS containing 5% FCS and 5 units/ml heparin. Peritoneal fluid was recovered, and red blood cells were lysed (RBC lysing buffer, BD Pharmingen). After counting, cells were centrifuged, resuspended in FACS buffer (PBS containing 2% BSA, 0.1% sodium azide, and 0.1% EDTA, pH 7.4), and incubated with anti-Fc γ RII/III antibodies (2.4G2, BD Pharmingen). Two separate groups of cells were stained: (i) panleukocyte mAb (anti-CD45-APC, 30-F11, BD Pharmingen) with mAbs for CD3-positive and natural killer (NK) cells (17A2-FITC, BD Pharmingen and DX5-PE, Miltenyi Biotec, Auburn, CA) and (ii) panleukocyte mAb with mAbs for neutrophils and macrophages (Gr1-FITC, BD Pharmingen and F4/80-PE, eBioscience, San Diego). Isotype control Abs were used according to the manufacturer's recommendations. Cells were washed and fixed in 2% EM-grade formaldehyde (Ted Pella). Analysis was performed on a FACSCalibur cytometer using CELLQUEST software (BD Biosciences).

AAT Oxidation by Myeloperoxidase (MPO)–H₂O₂ System. As described in ref. 17, hAAT (4 mg/ml) was incubated at 37°C for 45 min with MPO (1 unit/ml, Sigma), H₂O₂ (80 μ M, Sigma), and NaCl (2.5 mM) in PBS. The reaction was terminated by boiling for 1 h followed by filter-centrifugation (molecular weight 30,000 cutoff, Micron Bioseparations, Bedford, MA). Inhibition of elastase was evaluated 30 min after coincubation of oxidized AAT with porcine elastase (Sigma), as described in ref. 17.

Cytokine Assays. IFN γ was determined by using specific ELISA (R & D Systems). TNF α and macrophage inflammatory protein 1 α (MIP-1 α) were detected by electrochemiluminescence assay, as described in ref. 18. The amount of chemiluminescence was determined by using an Origen analyzer (BioVeris, Gaithersburg, MD).

Detection of Membrane TNF α and MHC Class II. Membrane TNF α on islet cells was detected by modification of a method used for the detection of membrane TNF α on human peripheral blood mononuclear cells (19). A single-cell suspension of islets was incubated with anti-mTNF α -PE mAb (MP6-XT22-PE, eBioscience) or anti-MHC class II (M5/114.15.2, BD Pharmingen).

Statistical Analysis. Comparisons between groups were analyzed by two-sided *t* test or by ANOVA for experiments with more than two subgroups. Results are presented as mean (\pm SEM).

Results

AAT Prolongs Islet Allograft Survival. Islets isolated from DBA/2 mice (H-2^d) were transplanted under the left renal capsule of STZ-induced hyperglycemic C57BL/6 mice (H-2^b). Blood glucose was followed throughout the study (Fig. 1*a*). Untreated recipient mice exhibited a rise in glucose levels after a short period of normoglycemia, reflecting the occurrence of acute graft failure. hAAT or albumin control was injected i.p. 1 day before transplantation and every 3 days thereafter. Recipient mice that received the full AAT treatment protocol exhibited prolonged graft function (Fig. 1*a* and *b*). As depicted in Fig. 1*b*, partial treatment protocols, i.e., hAAT on days –1, 1, and 3 (early AAT) or on day 2 and thereafter (late AAT), did not prolong allograft survival.

hAAT-treated mice developed anti-hAAT antibodies (Fig. 1*c* and *d*). To ascertain that the antibodies were responsible for the reduction in the protective effect of hAAT, a group of mice was preexposed (“immunized”) to hAAT. The mice were injected i.p. with 10 mg of hAAT at intervals of 1 week for a total of four




Fig. 1. Prolonged survival of islet allografts by treatment with AAT. Islets from DBA/2 mice (H-2^d) were transplanted under the renal capsule of STZ-induced hyperglycemic C57BL/6 mice (H-2^b). (a) Glucose levels from days 6–18. Control consists of graft recipients that were untreated ($n = 3$) or treated every 3 days (from day –1) with human albumin (6 mg, $n = 3$). Prolonged islet graft survival is observed in mice treated every 3 days (from day –1) with hAAT (2 mg, $n = 10$). *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ between glucose levels on the same day. (b) Treatment protocols. Control and full AAT treatments are represented in *a*. Shown in *b* are AAT only on days –1, 1, and 3 (2 mg, $n = 3$; Early AAT) and AAT from day 2 and every 2 days thereafter (Late AAT) (2 mg, $n = 3$). The day that glucose levels exceed 300 mg/dl is indicated as Rejection. (c) Effect of mouse anti-hAAT antibodies. The dashed line indicates posttransplantation glucose levels of a mouse (1 representative of 3) under the full AAT treatment protocol (see *a* and *b*) that was immunized by prior administrations of hAAT. The solid line indicates glucose levels of a nonimmunized mouse (1 representative of 10) treated under the full AAT treatment protocol. The arrow indicates the day of detection of treatment-induced anti-hAAT antibodies. (d) Comparison of day 15 posttransplantation glucose levels in mice that were under full treatment protocol with albumin (ALB) ($n = 3$) or AAT (nonimmunized, $n = 10$; immunized, $n = 3$). Of the AAT-alone-treated group, antibodies were detected in 3 of 3 immunized mice and in 6 of 10 nonimmunized mice. **, $P = 0.005$ between mice that produced antibodies and mice that did not.

times and were transplanted 2 months later with allogeneic islets. The mice were treated with the full AAT protocol, despite exhibiting high titers of specific antibodies before engraftment. These recipients, not unexpectedly, exhibited rapid graft rejection (Fig. 1*c*). In addition, day 15 from transplantation was chosen to depict an association between antibody formation and loss of hAAT-protective activity; at this time point, hAAT-treated mice were divided into those that exhibited anti-hAAT antibodies and those that did not. As shown in Fig. 1*d*, all antibody-positive mice were hyperglycemic, and all antibody-negative mice were normoglycemic.

AAT Inhibits Cellular Infiltration. Two models of cell emigration were performed: ThG-elicited peritoneal infiltration, and cellular infiltration elicited by i.p. injection of major-MHC-incompatible fibroblasts. For both setups, C57BL/6 mice were pretreated with saline, human albumin, hAAT, or oxidized hAAT.

ThG Model. Peritoneal lavage was performed 24 and 48 h after ThG injection, and cells were counted and identified by FACS




Fig. 2. Effect of AAT on ThG-elicited peritoneal cellular infiltrates. Mice were administered saline, albumin (ALB), AAT, or oxidized AAT (oxid.AAT), followed by either saline or ThG (3% wt/vol, $n = 3$ per group). Peritoneal lavage was performed on separate groups after 24 and 48 h. (a) Total cell population of lavaged cells of saline- (open bars) or AAT-treated (5 mg, black bars) ThG-injected mice. *, $P < 0.05$; ***, $P < 0.001$. (b) Percent cell population from saline-treated mice at 48 h. **, $P < 0.01$. CT, control. (c) Oxidation of AAT. AAT was subjected to oxidative radicals, and loss of activity was assessed in an elastase assay. Activity of elastase in the absence of native AAT was set at 100%, and the percentage of activity in the presence of native and oxidized AAT was calculated ($n = 3$). ***, $P < 0.001$. (d) Identification of elicited macrophages (M ϕ) and neutrophils. Peritoneal infiltrates from 48-h lavages of ALB- (6 mg) and AAT-treated (6 mg) ThG-injected mice were identified by FACS analysis. Macrophages and neutrophils were identified on the basis of F4/80 and Gr1 vs. side-scatter flow cytometry profiles. (Left) Quantified FACS results ($n = 3$). (Right) FACS analysis, representative graphs ($n = 3$). PMN, polymorphonuclear leukocyte. (e) Production of TNF α by cultured splenocytes from ThG-injected mice. Splenocytes were harvested and washed 48 h after i.p. injection of 1 ml ThG or saline (CT) in mice that were pretreated with albumin (ThG/ALB, 5 mg) or AAT (ThG/AAT, 5 mg). After 48 h of culture in the absence of inducers, levels of secreted TNF α and IFN γ were determined. Mean \pm SEM from ThG/ALB group ($n = 3$ per group).

analysis. As shown in Fig. 2a, at 24 and 48 h, the total cell count was lower in mice pretreated with AAT. At 48 h, the total cell count in peritoneal lavage of AAT-treated mice was 50% of that in control mice (Fig. 2a and b). The total cell count in mice that received albumin control was similar to that of saline-treated mice. Oxidized AAT that had lost its *in vitro* anti-elastase activity (Fig. 2c) failed to inhibit cellular infiltration (Fig. 2b). The decrease in the total cell count is primarily attributed to a decrease in the number of neutrophils, identified by their GR-1^{high}/intermediate side-scatter (SSC) profile (20) (Fig. 2d Left) quantified FACS analysis and Fig. 2d Right, FACS analysis. No major differences were observed with the infiltration of macrophages, identified by their F4/80^{int}, GR-1^{int}, intermediate SSC profile (20), which is distinct from the F4/80^{very high}, GR-1^{low}, high-SSC profile of resident macrophages. Splens were removed 48 h after ThG injection, and splenocytes were cultured. In the absence of inducers, the splenocytes spontane-




Fig. 3. Effect of AAT on MHC-incompatible fibroblast-elicited peritoneal cellular infiltrates. Mice (C57BL/6; H-2^b) were administered saline or AAT (1 mg) followed by NIH 3T3 cells (1×10^7 cells; H-2^d). Peritoneal lavage was performed daily on days 1–5, and cell subpopulations were identified by FACS analysis ($n = 3$ per treatment). (a) Cell numbers. The number of cells in each subpopulation was calculated from the percentages obtained by FACS analysis and total number of cells in the infiltrate. *, $P < 0.05$; **, $P < 0.01$ between cell numbers on the same day. (b) Representative FACS analysis. (c) Effect of AAT on intensity and function of infiltrate elicited by islet allograft. (Left) Hematoxylin and eosin (H&E) staining of day-7 islet allografts. A section of AAT-treated islet graft (in white frame) is compared with an equivalent section from an ALB-treated diabetic recipient mouse (full AAT treatment protocol, see Fig. 1a). The arrow indicates the border between the islet and surrounding infiltrate. (Right) Immunohistochemistry for insulin in islet grafts on day 15. A section of autologous islet graft (in white frame) represents intact transplanted islets and is compared with equivalent sections of allografts of AAT- and ALB-treated recipient mice. R, renal parenchyma; G, graft; C, renal capsule.

ously produced TNF α (Fig. 2e). Pretreatment of mice with AAT decreased TNF α release from cultured splenocytes (mean 96.4%). A similar suppression was found in IFN γ (mean 95.0%), implying a sustained effect of AAT on isolated, washed splenocytes 48 h after *in vivo* exposure of the mouse to ThG.

Major-MHC-Incompatible Fibroblast Model. Freshly harvested NIH 3T3 cells, derived from BALB/c mice (H-2^d), were injected i.p. into C57BL/6 mice (H-2^b). Lavage was performed on days 1–5. As shown in Fig. 3a, the introduction of allogeneic cells evoked a cellular infiltrate that consisted of early appearing neutrophils and activated macrophages and late appearing CD3⁺ and NK cells (Fig. 3a and b). hAAT-treated mice exhibited a reduction in neutrophils by 53%, CD3⁺ by 44%, and NK cells by 89%.

To evaluate infiltration into grafted islets, grafts from AAT- and ALB-treated recipient mice were examined. As depicted in Fig. 3c Left, a cellular infiltrate is demonstrable regardless of AAT treatment and includes neutrophils and lymphocytes.




Fig. 5. Effect of AAT on TNF α in islets. (a) Islets from C57BL/6 mice were cultured (100 islets per well, in triplicate) in the presence of AAT (0.5 mg/ml) or TACE inhibitor (10 mM) 1 h before stimulation by IFN γ (5 ng/ml) and IL-1 β (10 ng/ml). (Left) Mean (\pm SEM) change in TNF α levels in supernatants after 72 h of incubation. (Right) Mean (\pm SEM) fold change in membrane TNF α on islet cells after 5 h of incubation. ***, $P < 0.001$ compared with control (CT) levels in the absence of AAT. (Lower) Representative FACS analysis of membrane TNF α on stimulated islet cells in the absence (open area) or presence (shaded area) of AAT. Events are gated for CD45. (b) *In vivo* STZ-induced beta cell toxicity. C57BL/6 mice were injected with saline ($n = 3$), AAT (5 mg, $n = 3$) or soluble p55 TNF receptor (p55 TNFR, 1 mg/kg of body weight, $n = 3$) or administered oral TACE inhibitor (TACEi, 60 mg/kg of body weight, $n = 6$) 1 day before injection of STZ (225 mg/kg of body weight, i.p.). Subsequently, AAT and soluble TNF receptor were injected daily, and TACE inhibitor was administered twice a day. At 48 h, mean (\pm SEM) glucose levels are compared with those of normal littermates ($n = 3$). *, $P < 0.05$; **, $P < 0.01$, compared with saline-treated, STZ-injected mice.

hepatic injury (25). Normal human plasma contains 0.8–2.4 mg/ml AAT (26).

We demonstrate here that i.p. ThG induced local immune-cell migration that was inhibited by AAT. Specifically, ThG-induced infiltration contained 66% fewer neutrophils, the presence of which is detrimental to islet survival (27). The effect of AAT on neutrophil function is well documented; AAT blocks IL-8 secretion from human leukocytes (28) and reduces whole-lung expression of macrophage inflammatory protein 2, monocyte chemoattractant protein 1 (MCP-1), and intercellular adhesion molecule 1 (11). AAT reduces neutrophil infiltration into kidneys during ischemia/reperfusion injury (10) and into lung tissue after intratracheal silica administration (11). The essential inhibitory effect of AAT on neutrophils probably involves direct inhibition of elastase, the prototypic neutrophil protease and an avid substrate for AAT anti-protease activity. Elastase can promote islet graft destruction not only by facilitation of neutrophil migration (29) but also by induction of platelet-activating factor (6) and processing of tyrosine-tRNA synthase into fragments with IL-8-like properties (30).

Macrophages infiltrate islets before the onset of insulinitis in nonobese diabetic mice (31), and the depletion of macrophages protects transplanted islets from acute rejection in rats (32). It was shown that islets produce MCP-1 (33) and that islet rejection is associated with an increased expression of intra-graft macrophage chemokines and their receptors (34). Indeed, knockout mice for these receptors exhibit prolongation of islet allograft survival (34, 35). Once activated inside transplanted tissues, macrophages can secrete TNF α and IL-1 β , which cause cell damage before antigen recognition (36). Therefore, it was interesting to find that macrophages reside within freshly isolated islets (as also described by Toyama *et al.* in ref. 37).

i.p. injection of allogeneic NIH 3T3 cells evoked infiltration of macrophages and neutrophils on days 1 and 2 after injection and of CD3 $^+$ and NK cells on days 4 and 5 after injection. The intensity of the latter type of infiltrate was decreased by admin-

istration of AAT before injection of allogeneic cells but not by administration of AAT 3 days after cell injection (data not shown), indicating that the decrease in CD3 $^+$ and NK cells is secondary to AAT-induced suppression of the preceding infiltrate. Concurrently, late treatment with AAT was ineffective in prolonging islet graft survival, whereas full AAT treatment diminished infiltration of neutrophils and lymphocytes and was associated with improved islet viability and intra-graft insulin content.

AAT decreased *in vitro* NO production by IL-1 β /IFN γ -stimulated islets, resulting in enhancement of islet viability and intact glucose-mediated insulin induction. *In vivo*, AAT protected islets from STZ-induced toxicity, as demonstrated by a lower degree of hyperglycemia after 48 h. In that experiment, we observed that the relative number of viable beta cells inside islets was proportional to the decrease in serum glucose levels, as assessed by insulin content. Considering the ability of AAT to diminish NO production by islet cells, these data suggest that AAT interferes with NO-dependent events that mediate STZ toxicity (38).

MHC class II antigens on the surface of islet cells are critical for directing immune responses against islets (39). Here, we show that AAT reduces MHC class II expression in islets to levels below those found in IL-1 β /IFN γ -stimulated islets and in unstimulated islets. Because the procedure of islet-isolation provokes the activation of inflammatory pathways (40), the ability of AAT to decrease islet expression levels of MHC class II below isolation-induced levels is highly relevant.

In the presence of AAT, IL-1 β /IFN γ -stimulated islets produced strikingly less TNF α (mean decreases of 89.9% and 99.2% at 0.5 mg/ml and 1.0 mg/ml AAT, respectively). Because AAT blocks TNF α release from stimulated human peripheral blood mononuclear cells without affecting TNF α mRNA levels (41), we believe that AAT might also inhibit the release of TNF α from islet cells. Membrane TNF α is released from cell surfaces by the action of the metalloproteinase TACE (21). Accordingly, inhibitors of TACE reduce TNF α release and increase the amounts of membrane TNF α (19). Here, we demonstrate that, in the presence of AAT, TNF α accumulates on the surface of IL-1 β /IFN γ -stimulated CD45 $^+$ islet cells. TACE-inhibition may be relevant for the process of graft rejection, because an inhibitor of TACE decreased injury in a rat model of posttransplant lung injury (42). Although there are no reports that describe prolongation of islet graft survival by TACE inhibition alone, locally secreted TNF α was found to be detrimental to islet graft function (43), and islet allograft survival was prolonged after *ex vivo* transduction with adenovirus-encoded soluble type 1 TNF receptor decoy (44).

In an animal model of renal ischemia/reperfusion injury, administration of human AAT (0.5 mg) protected kidney function and was associated with reduced neutrophil infiltration, intra-graft TNF α levels, and frequency of apoptosis (10). It is recognized that ischemia/reperfusion injury during human renal transplantation correlates with poor clinical outcome (45). Specifically, in gene expression studies performed on biopsies of renal grafts at 15-min postperfusion (“zero-hour”), Avihing-sanon *et al.* (45) demonstrate that intra-graft proinflammatory and early immune-activating gene-expression patterns correlate with poor transplant outcome; abundance of TNF α and ICAM-1 transcripts and graft ischemic time individually predicted acute rejection, and suboptimal expression of antiapoptotic genes predicted delayed graft function. The ability of AAT to diminish inflammatory parameters and cytopathic tissue injury in the ischemia/reperfusion model may provide the basis for the diminished alloimmune response and prolonged graft survival in the islet-transplantation model observed here.

Our data suggest, therefore, that the mechanism by which AAT prolongs islet graft survival involves multiple aspects of

immune and inflammatory responses and, importantly, islet cell viability. (i) AAT reduces the degree of inflammation below that which damages islets, (ii) AAT promotes the viability of islets in the presence of inflammatory agents, (iii) AAT decreases islet immunogeneity in the form of low MHC class II expression, and (iv) AAT reduces infiltration of immune cells elicited by a variety of inducers, including those that are independent of MHC recognition. This impressive array of activities, which includes the crucial preservation of islet viability, is distinctive to AAT and has not been reported to be the outcome of other clinical or experimental immunosuppressive regimens.

1. Sato, T., Inagaki, A., Uchida, K., Ueki, T., Goto, N., Matsuoka, S., Katayama, A., Haba, T., Tominaga, Y., Okajima, Y., et al. (2003) *Transplantation* **76**, 1320–1326.
2. Ricordi, C. & Strom, T. B. (2004) *Nat. Rev. Immunol.* **4**, 259–268.
3. Couzin, J. (2004) *Science* **306**, 34–37.
4. Kobayashi, N., Okitsu, T., Lakey, J. R. & Tanaka, N. (2004) *J. Artif. Organs* **7**, 1–8.
5. Breit, S. N., Wakefield, D., Robinson, J. P., Luckhurst, E., Clark, P. & Penny, R. (1985) *Clin. Immunol. Immunopathol.* **35**, 363–380.
6. Camussi, G., Tetta, C., Bussolino, F. & Baglioni, C. (1988) *J. Exp. Med.* **168**, 1293–1306.
7. Song, S., Goudy, K., Campbell-Thompson, M., Wasserfall, C., Scott-Jorgensen, M., Wang, J., Tang, Q., Crawford, J. M., Ellis, T. M., et al. (2004) *Gene Ther.* **11**, 181–186.
8. Fischer, D. C., Siebertz, B., van de Leur, E., Schiwy-Bochat, K. H., Graeve, L., Heinrich, P. C. & Haubeck, H. D. (1999) *Arthritis Rheum.* **42**, 1936–1945.
9. Knoell, D. L., Ralston, D. R., Coulter, K. R. & Wewers, M. D. (1998) *Am. J. Respir. Crit. Care Med.* **157**, 246–255.
10. Daemen, M. A., Heemskerk, V. H., van't Veer, C., Denecker, G., Wolfs, T. G., Vandenaabeele, P. & Buurman, W. A. (2000) *Circulation* **102**, 1420–1426.
11. Churg, A., Dai, J., Zay, K., Karsan, A., Hendricks, R., Yee, C., Martin, R., MacKenzie, R., Xie, C., Zhang, L., et al. (2001) *Lab. Invest.* **81**, 1119–1131.
12. Jie, Z., Cai, Y., Yang, W., Jin, M., Zhu, W. & Zhu, C. (2003) *Chin. Med. J. (Engl. Ed.)* **116**, 1678–1682.
13. Salvalaggio, P. R., Deng, S., Ariyan, C. E., Millet, I., Zawalich, W. S., Basadonna, G. P. & Rothstein, D. M. (2002) *Transplantation* **74**, 877–879.
14. Thomas, H. E., Darwiche, R., Corbett, J. A. & Kay, T. W. (2002) *Diabetes* **51**, 311–316.
15. Noguchi, H., Matsushita, M., Okitsu, T., Moriwaki, A., Tomizawa, K., Kang, S., Li, S. T., Kobayashi, N., Matsumoto, S., Tanaka, K., et al. (2004) *Nat. Med.* **10**, 305–309.
16. Song, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B. J., Atkinson, M. & Flotte, T. R. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 14384–14388.
17. Wasil, M., Halliwell, B., Hutchison, D. C. & Baum, H. (1987) *Biochem. J.* **243**, 219–223.
18. Fantuzzi, G. & Dinarello, C. A. (1998) *Eur. Cytokine Network* **9**, 85–92.
19. Bueno, C., Rodriguez-Caballero, A., Garcia-Montero, A., Pandiella, A., Almeida, J. & Orfao, A. (2002) *J. Immunol. Methods* **264**, 77–87.
20. Gordon, S., Lawson, L., Rabinowitz, S., Crocker, P. R., Morris, L. & Perry, V. H. (1992) *Curr. Top. Microbiol. Immunol.* **181**, 1–37.
21. Black, R. A. (2002) *Int. J. Biochem. Cell Biol.* **34**, 1–5.
22. Beck, G., Bottomley, G., Bradshaw, D., Brewster, M., Broadhurst, M., Devos, R., Hill, C., Johnson, W., Kim, H. J., Kirtland, S., et al. (2002) *J. Pharmacol. Exp. Ther.* **302**, 390–396.
23. Santos, A. A., Shapiro, L., Lynch, E. A., Brown, E. F., Chambers, E., Jacobs, D. O., Dinarello, C. A., Mannick, J. & Wilmore, D. W. (1993) *Surg. Forum* **44**, 119–121.
24. Libert, C., Van Molle, W., Brouckaert, P. & Fiers, W. (1996) *J. Immunol.* **157**, 5126–5129.
25. Niehorster, M., Tiegs, G., Schade, U. F. & Wendel, A. (1990) *Biochem. Pharmacol.* **40**, 1601–1603.
26. Macen, J. L., Upton, C., Nation, N. & McFadden, G. (1993) *Virology* **195**, 348–363.
27. Allison, J., Georgiou, H. M., Strasser, A. & Vaux, D. L. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 3943–3947.
28. Nita, I., Hollander, C., Westin, U. & Janciauskiene, S. M. (2005) *Respir. Res.* **6**, 12.
29. Cai, T. Q. & Wright, S. D. (1996) *J. Exp. Med.* **184**, 1213–1223.
30. Wakasugi, K. & Schimmel, P. (1999) *Science* **284**, 147–151.
31. Lee, K. U., Amano, K. & Yoon, J. W. (1988) *Diabetes* **37**, 989–991.
32. Bottino, R., Fernandez, L. A., Ricordi, C., Lehmann, R., Tsan, M. F., Oliver, R. & Inverardi, L. (1998) *Diabetes* **47**, 316–323.
33. Johansson, U., Olsson, A., Gabriellsson, S., Nilsson, B. & Korsgren, O. (2003) *Biochem. Biophys. Res. Commun.* **308**, 474–479.
34. Abdi, R., Means, T. K., Ito, T., Smith, R. N., Najafian, N., Jurewicz, M., Tchipachvili, V., Charo, I., Auchincloss, H., Jr., Sayegh, M. H. & Luster, A. D. (2004) *J. Immunol.* **172**, 767–775.
35. Baker, M. S., Chen, X., Rotramel, A. R., Nelson, J. J., Lu, B., Gerard, C., Kanwar, Y. & Kaufman, D. B. (2003) *Surgery* **134**, 126–133.
36. Teshima, T., Ordemans, R., Reddy, P., Gagrin, S., Liu, C., Cooke, K. R. & Ferrara, J. L. (2002) *Nat. Med.* **8**, 575–581.
37. Toyama, H., Takada, M., Tanaka, T., Suzuki, Y. & Kuroda, Y. (2003) *Transplant Proc.* **35**, 1503–1505.
38. Wada, R. & Yagihashi, S. (2004) *Virchows Arch.* **444**, 375–382.
39. McInerney, M. F., Rath, S. & Janeway, C. A., Jr. (1991) *Diabetes* **40**, 648–651.
40. Abdelli, S., Ansite, J., Roduit, R., Borsello, T., Matsumoto, I., Sawada, T., Allaman-Pillet, N., Henry, H., Beckmann, J. S., Hering, B. J. & Bonny, C. (2004) *Diabetes* **53**, 2815–2823.
41. Scuderi, P., Dorr, R. T., Liddil, J. D., Finley, P. R., Meltzer, P., Raitano, A. B. & Rybski, J. (1989) *Eur. J. Immunol.* **19**, 939–942.
42. Goto, T., Ishizaka, A., Kobayashi, F., Kohno, M., Sawafuji, M., Tasaka, S., Ikeda, E., Okada, Y., Maruyama, I. & Kobayashi, K. (2004) *Am. J. Respir. Crit. Care Med.* **27**, 27.
43. de Vos, P., Smedema, I., van Goor, H., Moes, H., van Zanten, J., Netters, S., de Leij, L. F., de Haan, A. & de Haan, B. J. (2003) *Diabetologia* **46**, 666–673.
44. Machen, J., Bertera, S., Chang, Y., Bottino, R., Balamurugan, A. N., Robbins, P. D., Trucco, M. & Giannoukakis, N. (2004) *Gene Ther.* **11**, 1506–1514.
45. Avihingsanon, Y., Ma, N., Pavlakis, M., Chon, W. J., Uknis, M. E., Monaco, A. P., Ferran, C., Stillman, I., Schachter, A. D., Mottley, C., et al. (2005) *J. Am. Soc. Nephrol.* **16**, 1542–1548.
46. Wewers, M. D., Casolaro, M. A., Sellers, S. E., Swayze, S. C., McPhaul, K. M., Wittes, J. T. & Crystal, R. G. (1987) *N. Engl. J. Med.* **316**, 1055–1062.

This work was supported, in part, by National Institutes of Health Grants AI 15614 and HL-68743 and Colorado Cancer Center Grant CA-04 6934.